Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 5.37IPCO.TO -0.2DC.A.TO 0.28NESN-SIX 0MCK 27.62GOOG -1.47XLV 0.985TEVA 0.82
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.45
+0.48 (1.70%)
as of Aug 25, 2026, 5:51:24 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK

Pfizer Inc(PFE)

Nov 11, 2004
Trading close to a 52 week low. Trading at about 11.5 X next year's earnings. A contrarian pick when looked at with the US$. A first class company. Have about $20 billion in net free cash flow.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$27.15

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 10, 2004
Stock has been extremely disappointing. Has the best fundamentals of all the drug stocks except for J & J. Drug sector has come under a number of significant pressures.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$27.47

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 02, 2004
An excellent company, but a poor stock. The whole pharmaceutical sector has been under pressure for 2/3 years.
Photo of Ian NakamotoIan Nakamoto
Owned
Unlock Rating
$28.70

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 29, 2004
SHould do well if Bush wins the election.
Photo of Alison DeansAlison DeansUnlock Rating
$28.95

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 27, 2004
Pharmaceuticals are cheaper than he has ever seen them. Cheap. Trading at low multiples.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$29.04

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 26, 2004
30% discount between their model price and current stock price.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$28.33

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 22, 2004
Has been beaten up. Has all the good things going for it according to analysts. Strong cash flow.
Photo of Robert StovallRobert Stovall
Owned
Unlock Rating
$27.74

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 20, 2004
Has had a very disappointing performance. Big pharmas have some issues facing them with regards to generic drugs. An extremely good company. Ran into problems because of their recall of Vioxx.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$28.30

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
HOLD

Pfizer Inc(PFE)

Oct 12, 2004
Has dropped in sympathy with Merk and their recall of Vioxx as they have a similar product which is a big seller. Pharmaceutical industry as a whole has been hurt by generics and lagging R&D. Could drop further. All money is made in the US.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$29.86

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 07, 2004
Thinks its been oversold. Big pharmas have been in the dog house for at least 5 years.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$29.99

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 01, 2004
Interested in companies that have very good earnings growth and visibility. Have a pipeline that is not being valued appropriately.
Photo of Mary FarrellMary Farrell
Owned
Unlock Rating
$30.97

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 24, 2004
Best value in the market is in quality names. Best pharmaceutical company in the world. Just hasn't gone anywhere. New products are going into the pipeline.
Photo of Nicholas SargenNicholas Sargen
Owned
Unlock Rating
$29.66

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Sep 13, 2004
(A Top Pick Dec 29/03. Down 9%.) Have bought more on the dips. Health care industry in the US has suffered for the last 2 years. Showing strong revenue growth.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$32.13

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 10, 2004
A lot of drug stocks have been under pressure. All of the US drug companies are in a favorable position of having reasonable growth prospects.
Photo of Ray SteeleRay Steele
No
Unlock Rating
$31.86

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 08, 2004
Feels the US drug companies will continue to have tough sledding because of generics. This company is better equipped to fight that. Growth through acquisition.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$32.77

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 706 to 720 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.69$101.18
TFPM 0$
OGC.TO 0.03$43.25
SLB -0.545$53.455
ARG.TO 0.53$8.75

Today's Top Picks

SII.TO 5.37$192.56
IPCO.TO -0.2$35.02
DC.A.TO 0.28$5.43
NESN-SIX 0$
MCK 27.62$901.41

Popular Articles

Latest Sell Signals

RKLB -1.16$67.12
INTC 0.36$87.62
MSFT 3.13$490.44
WSP.TO -3.61$188.67
CLS.TO 12.54$419.9

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like